Sonnet BioTherapeutics Holdings, Inc.
SONN
$3.47
$0.092.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,688.91% | 977.59% | 673.99% | -87.42% | -67.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,688.91% | 977.59% | 673.99% | -87.42% | -67.76% |
| Cost of Revenue | 133.27% | 123.09% | 145.34% | -9.82% | -135.19% |
| Gross Profit | -114.30% | -101.46% | -111.30% | -442.26% | 135.97% |
| SG&A Expenses | 28.77% | 42.01% | 26.64% | -13.96% | -22.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.11% | 15.88% | -1.15% | -37.34% | -45.78% |
| Operating Income | -14.52% | -8.83% | 7.19% | 36.95% | 45.61% |
| Income Before Tax | -67.78% | -55.79% | 35.88% | 60.51% | 64.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.76% | -57.67% | 34.78% | 60.51% | 64.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.76% | -57.67% | 34.78% | 60.51% | 64.65% |
| EBIT | -14.52% | -8.83% | 7.19% | 36.95% | 45.61% |
| EBITDA | -14.55% | -8.84% | 7.19% | 36.97% | 45.63% |
| EPS Basic | 72.12% | 73.12% | 90.48% | 95.56% | 95.36% |
| Normalized Basic EPS | 72.44% | 73.30% | 90.56% | 95.56% | 95.36% |
| EPS Diluted | 72.16% | 73.14% | 90.45% | 95.55% | 95.35% |
| Normalized Diluted EPS | 72.48% | 73.33% | 90.53% | 95.55% | 95.35% |
| Average Basic Shares Outstanding | 470.66% | 422.34% | 336.67% | 404.64% | 484.48% |
| Average Diluted Shares Outstanding | 460.78% | 410.45% | 340.18% | 411.09% | 494.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |